Navigation Links
AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
Date:12/7/2009

ward to the initiation of the Phase 3 study in this same indication, this month", stated Juergen Engel, Ph.D., President and CEO at AEterna Zentaris.

Keryx has been granted a Special Protocol Assessment (SPA) from the FDA for the upcoming Phase 3 study of perifosine in multiple myeloma. Additionally, the FDA has granted perifosine Orphan Drug and Fast Track designations in this indication.

About Perifosine (KRX-0401)

Perifosine is a novel oral anticancer agent that modulates several key signal transduction pathways, including Akt, MAPK, and JNK that have been shown to be critical for the survival of cancer cells. Perifosine has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. Perifosine is currently in Phase 2 clinical development for multiple tumor types, with a Phase 3 in multiple myeloma, under Special Protocol Assessment (SPA), pending commencement by year-end. Perifosine has also received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma.

About Multiple Myeloma

Multiple myeloma, a cancer of the plasma cell, is an incurable but treatable disease. Multiple myeloma is the second most-common hematologic cancer, representing 1% of all cancer diagnoses and 2% of all cancer deaths. According to the American Cancer Society, in 2009 there will be an estimated 20,580 new cases of multiple myeloma and an estimated 10,500 deaths from multiple myeloma in the United States. To date, several FDA approved therapies exist for the treatment of multiple myeloma. Despite this progress, patients continue to relapse, become refractory to prior treatments and eventually die from their disease. Thus, new therapies are needed to treat these patients and extend their survival.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global biopharmaceutical compa
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... -- Donald Fresne, President and CEO of Egenix, Inc. is pleased ... to its Scientific Advisory Committee. Dr. Vagner, a ... , performed research at Embl (European Molecular Biology Laboratory) Heidelberg, ... institute of health and medical research. He is a Research ... Orsay, France , and at the Gustave ...
(Date:9/16/2014)... September 16, 2014 Pharma ... to position themselves for their 89th year ... and encoding, Pharma Packaging Solutions is preparing ... and software and new procedures. Establishing training ... Manufacturing Practices (cGMP), Pharma Packaging Solutions will ...
(Date:9/16/2014)... Denmark , Sept. 16, 2014  Ascendis ... innovative TransCon technology to address significant unmet medical ... ongoing Phase 2 pediatric study to evaluate once-weekly ... deficiency, or GHD.  The full interim results will ... the GRS and IGF Society, being held October ...
(Date:9/16/2014)... RENU 28, the world's first and only skin ... purchase in Australia and New Zealand in mid-August . , ... The tour will make stops in Brisbane on September 16, ... Sydney on the 20th, and Melbourne on the 22nd. , ... and to educate people about the new product and business ...
Breaking Biology Technology:New Appointment to the Scientific Advisory Committee at Egenix, Inc. 2Adding Serialization Capabilities and Expanded Capacity, Pharma Packaging Solutions Is Preparing for 89th Year of Business 2Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Global Wellness Company Hosts ASEA Australia Tour September 16-22 2
... and improved seizure freedom versus placebo when ... (AEDs)- Phase III study supports recent U.S. ... Jan. 27 The new antiepileptic drug ... adult partial-onset epilepsy patients whose seizures were ...
... Canada, Jan. 27 InNexus Biotechnology Inc. (OTC Bulletin ... today that it has completed a second private placement ... placement that was completed 12 December 2008.The private placement, ... Debenture will be convertible into common shares of InNexus ...
... (CTI),(Nasdaq and MTA: CTIC) announced today that the ... Letter") from the Listing,Qualifications Staff (the "Staff") of ... not comply with Marketplace Rule 4350(i)(1)(C) when the,Company ... ("SMI"),and issued additional common shares to SMI shareholders. ...
Cached Biology Technology:Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy 2Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy 3Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy 4Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy 5InNexus Completes Previously Announced Private Placement 2Cell Therapeutics Receives Additional NASDAQ Notification 2Cell Therapeutics Receives Additional NASDAQ Notification 3Cell Therapeutics Receives Additional NASDAQ Notification 4
(Date:9/16/2014)... Philadelphia, PA, September 16, 2014 Schizophrenia is associated ... A growing body of research suggests that the relationship ... effort by patients to use nicotine to self-medicate symptoms ... new study, published in the current issue of ... authors found that the level of nicotine receptors in ...
(Date:9/16/2014)... responsible for practically all vital functions in an ... signals, transport particular substances and control immune system ... do not function independently of each other, but ... the protein networks, you find many similarities with ... TUM,s Chair of Plant Systems Biology. "Some proteins ...
(Date:9/15/2014)... processes from digestion to disease resistance. Despite the fact ... on the planet, more is known about belly-button bacteria ... and colleagues working on Panama,s Barro Colorado Island discovered ... home to more than 400 different kinds of bacteria. ... than 7,000 different kinds. , Bacteria in tropical forests ...
Breaking Biology News(10 mins):Smoking and schizophrenia linked by alterations in brain nicotine signals 2Good networkers make prime targets 2Smithsonian scientists discover tropical tree microbiome in Panama 2
... St. Louis, MO, June 1, 2010 Making food choices ... according to a new study comparing the nutritional content of ... the June issue of the Journal of the American ... diet consisting entirely of advertised foods would contain 25 times ...
... Arbor, Mich. University of Michigan scientists have provided the ... brain that influences the effectiveness of serotonin-related antidepressants, such as ... ahead of print in the journal Proceedings of the ... a more targeted treatment of depression and anxiety with fewer ...
... have identified three new susceptibility genes in a genome-wide ... by the Genome Institute of Singapore (GIS), a biomedical ... Research (A*STAR), and the Sun Yat-Sen University Cancer Centre, ... understanding of the important role played by host genetic ...
Cached Biology News:TV food advertisements promote imbalanced diets 2Animal study reveals new target for antidepressants 2Scientists find genes associated with throat cancer through study of over 10,000 subjects 2Scientists find genes associated with throat cancer through study of over 10,000 subjects 3
...
... organic acid analysis standard is ... organic salts; molecular weights range ... standard is provided for use ... and the organic acid analysis ...
Compound(s) tested through a broad panel of 38 ligand binding and enzyme assays targeting the Central Nervous System. Used to determine selectivity and potential CV/Renal liabilities of compounds....
Compound(s) tested through a broad panel of 38 ligand binding and enzyme assays targeting the Central Nervous System. Used to determine selectivity and potential GI liabilities of compounds....
Biology Products: